Does Insurance Cover Zepbound for Sleep Apnea?

Who qualifies for Zepbound for sleep apnea?

The label covers adults with obesity and moderate-to-severe OSA, but each payer sets its own coverage criteria on top of that. The paperwork a plan expects is the same as for any GLP-1 prior authorization; see what documentation gets a GLP-1 prior authorization approved.

Payers set their own coverage criteria. The FDA label establishes the drug's approved indication, while an insurer may impose additional coverage or prior-authorization requirements. Here is what the label says.

Zepbound is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. It also carries the OSA indication quoted above.

The OSA registration trials for Zepbound enrolled adults with moderate to severe OSA defined as an apnea-hypopnea index (AHI) of 15 or greater, in patients with obesity (BMI 30 kg/m2 or greater). Those two numbers describe the FDA trial population behind the label, not a universal payer requirement — individual insurers set their own coverage criteria, which may reference these numbers, use different thresholds, or ask for something else entirely. Check your plan's own policy rather than assuming these numbers apply to you. Both Zepbound indications are limited to adults; the safety and effectiveness of Zepbound have not been established in pediatric patients.

Form matters. Zepbound is administered exclusively as a subcutaneous injection; the FDA label describes it only as 'injection, for subcutaneous use' and no oral dosage form of Zepbound is listed in the label. There is no Zepbound pill.

Dosing for OSA is also on the label, and some plans check it. The recommended starting dosage of Zepbound for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks; the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. For the obstructive sleep apnea indication, the recommended Zepbound maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.

The trial results behind the indication, published in 2024: In SURMOUNT-OSA Trial 1 (participants not receiving PAP therapy at baseline), the apnea-hypopnea index decreased by 25.3 events/hour with tirzepatide versus 5.3 events/hour with placebo at week 52, a treatment difference of -20.0 events/hour (P<0.001). In SURMOUNT-OSA Trial 2 (participants receiving PAP therapy at baseline), the apnea-hypopnea index decreased by 29.3 events/hour with tirzepatide versus 5.5 events/hour with placebo at week 52, a treatment difference of -23.8 events/hour (P<0.001). Note that the drug was studied in both PAP-naive and PAP-treated patients. Whether your plan requires a PAP trial first is a plan-level rule, not a label rule.

Two safety points any prescriber will screen for, per the FDA label as of August 2026. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common adverse reactions reported in at least 5% of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.

How long does a prior authorization for Zepbound take?

For plans subject to the federal Marketplace rules, an insurer must generally notify you within 15 calendar days of a pre-service (prior authorization) benefit determination; rules can vary by plan and type of coverage. Preauthorization is a decision by a health insurer or plan that a health care service, treatment plan, prescription drug, or durable medical equipment is medically necessary. It is sometimes called prior authorization, prior approval, or precertification.

Measured's insurance concierge team submits prior authorizations on the patient's behalf and keeps the patient updated on the insurance plan's determination. Measured states that if prior authorization is approved, the patient pays only their plan's copay when picking up the medication from the pharmacy.

We cannot print a universal documentation checklist here, because each plan sets its own. What we can say is that if a plan denies the request, the notice must describe the plan's standard used to deny the claim and must inform you that a copy of the internal requirements will be provided free of charge upon request. That document tells you exactly what the plan wanted to see.

How does coverage differ between commercial plans and Medicare?

Commercial coverage is plan-specific and usually needs a prior authorization, while Medicare routes OSA prescriptions through regular Part D rather than the GLP-1 Bridge.

Two details on the Medicare Bridge. Only the Zepbound KwikPen formulation is included in the Medicare GLP-1 Bridge; the single-dose vial and single-dose pen formulations are not available through the program. And Zepbound is covered under the Medicare GLP-1 Bridge when used to reduce excess body weight and maintain weight reduction, so it is a weight-reduction pathway, not an OSA one. CMS is explicit about the split as of August 2026: beneficiaries with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH are ineligible for the Medicare GLP-1 Bridge even if they otherwise meet its clinical criteria, because those indications are eligible for regular Part D coverage; CMS directs them to obtain their GLP-1 through their Part D plan. So if your Zepbound is for sleep apnea, skip the Bridge and work your Part D plan's formulary and prior authorization process directly.

Medicaid rules vary by state and are not covered here. Manufacturer savings card terms change often and are not covered here either.

What can I do if my Zepbound claim is denied?

Read the denial notice for its stated reason, file an internal appeal, and escalate to external review if that fails. The deadlines below are the federal appeal rules that apply to most commercial and Marketplace plans, per HealthCare.gov — not every insurance arrangement in the country. If your Zepbound denial came through Medicare Part D, the process and timeline are different; see does Medicare cover Zepbound for Part D's own appeal deadline.

Start with the notice. When a plan denies a claim it is required to notify the enrollee of the reason the claim was denied, including the denial code and its corresponding meaning. If the denial was based on medical necessity, the notice must provide either an explanation of the scientific or clinical judgment for the determination or a notice that such an explanation will be provided free of charge upon request.

Then the clock. An enrollee must file an internal appeal within 180 days (6 months) of receiving notice that the claim was denied. An internal appeal must be completed within 30 days if the appeal concerns a service the enrollee has not yet received. An enrollee filing an internal appeal should submit any additional information they want the insurer to consider, such as a letter from the doctor. A denial on the ground that the requested service or treatment is not medically necessary can be appealed.

If the internal appeal fails, you can go outside the plan. An enrollee must file a written request for an external review within four months after the date they receive a notice or final determination from the insurer that the claim has been denied. Standard external reviews are decided as soon as possible and no later than 45 days after the request was received. The insurer is required by law to accept the external reviewer's decision. One dated caveat: HealthCare.gov states that an enrollee may be eligible for an extension until October 2, 2026 to request an external review if their deadline fell between July 1, 2026 and August 3, 2026 and their plan uses the HHS-Administered Federal External Review Process — which may apply to residents of Alabama, Florida, Georgia, Texas, Wisconsin, or a U.S. territory other than Puerto Rico, or to members of a state or local government plan in any state. See what an external review is and when to request one.

There is also a drug exceptions route. An enrollee has the right to follow their insurance company's drug exceptions process, which allows them to get a prescribed drug that is not normally covered by their health plan. Your doctor must confirm to the plan, orally or in writing, that the drug is appropriate for your condition.

What if I want to pay cash instead?

If coverage does not come through, Measured lists Zepbound as available "With and without insurance," with medication paid separately from membership, at a membership price starting from $49/mo as of August 2026; other self-pay options are on the medications page.

Does qualifying for Measured mean my plan will cover Zepbound?

No — a telehealth program's intake criteria and a payer's coverage criteria are two different things. Measured states its program is for adults with a body-mass index of 22 kg/m² or higher who also have a weight-related condition, or anyone with a BMI of 22 kg/m² or higher seeking an evidence-based medical approach to weight loss. That is Measured's intake threshold, not a payer's.